Patent classifications
A61L27/3834
Electrospinning of cartilage and meniscus matrix polymers
Disclosed herein are methods of producing a cartilaginous implant by producing a polymer scaffold composition by electrospinning a polymer solution onto a collector in order to obtain polymer fibers; crosslinking the polymer fibers; and adding a plurality of cells to the polymer scaffold composition, wherein the plurality of cells comprises cartilaginous cells to form a cartilaginous implant.
Apparatus and method for acoustophoretic printing
A method of acoustophoretic printing comprises generating an acoustic field at a first end of an acoustic chamber fully or partially enclosed by sound-reflecting walls. The acoustic field interacts with the sound-reflecting walls and travels through the acoustic chamber. The acoustic field is enhanced in a chamber outlet at a second end of the acoustic chamber. An ink is delivered into a nozzle positioned within the acoustic chamber. The nozzle has a nozzle opening projecting into the chamber outlet. The ink travels through the nozzle and is exposed to the enhanced acoustic field at the nozzle opening, and a predetermined volume of the ink is ejected from the nozzle opening and out of the acoustic chamber.
METHODS OF GENERATING, REPAIRING AND/OR MAINTAINING CONNECTIVE TISSUE IN VIVO
This invention relates to a method for generating, repairing and/or maintaining connective tissue in a subject. In one embodiment, the invention relates to a method for generating, repairing and/or maintaining cartilage tissue in a subject. The present invention also relates to a method of treating and/or preventing a disease in a subject arising from degradation and inflammation of connective tissue.
COMPOSITIONS AND METHODS FOR THE TREATMENT OF RETINAL DEGENERATION
Presented herein are compositions and methods for generating stem cell derived retinal tissue and isolated retinal progenitor cells for use in the treatment of retinal degenerative diseases and disorders.
BIOMIMETIC THREE-DIMENSIONAL DEVICE FOR DELIVERY OF THERAPEUTIC CELLS AND METHOD OF MAKING DEVICE
A cell delivery device and a method of producing a three dimensional device which is vascularized when implanted or topologically applied to human or animal body. Cell laden hydrogel (cells mixed with hydrogel) is casted or injected or 3D bioprinted in a leaf-like form, which contains removable parts (templates). After crosslinking, the templates are removed and the channel for vascularization is created. The device is ready for use in vitro or in vivo.
3D PRINTING BIO GEL AND METHOD OF USE
Collagen compositions, methods for preparing those collagen compositions, and 3D constructs formed from those collagen compositions are provided. In particular, methods of isolating collagen that exhibits an enhanced rate of gelling, such collagen compositions, and 3D constructs formed from such collagen compositions are provided.
METHOD AND DEVICE FOR IN VIVO TISSUE REGENERATION ON THE INTERIOR SURFACE OF HOLLOW ORGANS
Aspects of the disclosure relate methods and a synthetic cell delivery device for treating trauma present relative to the inner surface of a hollow organ such as an esophagus.
Multicellular lay-up process
Disclosed herein is a multicellular lay-up process. The process comprises the steps of: a) forming a core material, b) forming a capsule material, c) encapsulating the core with the capsule material, d) adding the capsule to a substrate, and e) exposing the capsule to at least one bioactivating agent.
Responsive elastic polymers and methods of making and using same
Disclosed herein are functionalized hyaluronic acid (HA), a responsive elastic polymer system comprising functionalized HA, and methods of fabrication and utilization of the same. This polymer system may be used for controlled local or systemic drug delivery release of analgesics, anesthetics, antibiotics and other drugs as well as tissue engineering articles.
Encapsulated liver tissue
The present disclosure provides an encapsulated liver tissue that can be used in vivo to improve liver functions, in vitro to determine the hepatic metabolism and/or hepatotoxicity of an agent and ex vivo to remove toxic compounds from patients' biological fluid. The encapsulated liver tissue comprises at least one liver organoid at least partially covered with a biocompatible cross-linked polymer. Processes for making the encapsulated liver tissue are also provided.